Conferences on Antiviral Research present a wealth of new information on novel drug development and the 21st annual meeting, held in Montreal between 13-17 April 2008, was no exception.
In summary, the safety, efficacy and compliance of GB05 have been significantly improved. Currently, phase III clinical trials for GB05 are on going in China. Kexing Biopharm has been deeply engaged ...
In a challenging market environment, Hemispherx Biopharma Inc (NYSE:AIM), trading under the ticker AIM, has seen its stock price touch a 52-week low, reaching a sobering $0.13, marking an 82% decline ...
Approximately 9.5% (US$15.7 million) of global funding was focused on drug development ... the only factor contributing to the absence of antiviral drugs against dengue, but there can be no ...
NanoViricides, Inc. (NYSE American:NNVC) (the 'Company') declared today that it is ready to fight the bird flu with its revolutionary ...
Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug ...
AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...
“With our deep expertise in antiviral drug development, continually expanding knowledge of COVID-19 and support from BARDA, we will advance the pre-exposure prophylaxis program for S-892216 at ...
"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases," said Anil R. Diwan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback